Design Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $464.00K, a 28.53% increase year-over-year.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $288.00K, a 13.39% increase year-over-year.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $361.00K, a 61.88% increase year-over-year.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $649.00K, a 36.06% increase from fiscal 2024.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $477.00K, a 56.39% increase from fiscal 2023.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $305.00K, a 10.03% decline from fiscal 2022.
- Design Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $339.00K, a 74.74% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $464.00K 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $649.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2025-06-30 | $361.00K 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $477.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2024-06-30 | $223.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $305.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $206.00K 10-Q · filed 2024-08-05 | |
| 2022-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $339.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $225.00K 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $194.00K 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |